Medicago signs strategic alliance with Mitsubishi Tanabe; Inovio gets H1N1 influenza vaccine patent;

> Canadian developer Medicago has signed a strategic alliance with Japanese company Mitsubishi Tanabe Pharma to develop and commercialize at least three new vaccines. Medicago release

> Emergent BioSolutions ($EBS) has received a multi-year grant from the National Institute of Allergy and Infectious Diseases (NIAID) to support its tuberculosis vaccine MVA85A, currently in development through a partnership between Aeras and the Oxford-Emergent Tuberculosis Consortium. Emergent release

> GenVec's ($GNVC) respiratory syncytial virus vaccine triggers immune responses in animal models, according to data presented at the Keystone Symposium on Viral Immunity and Host Gene Influence. GenVec release

> The U.S. Patent Office has granted Inovio Pharmaceuticals ($INO) a patent relating to H1N1 influenza for its SynCon universal influenza vaccine. Inovio release

> Vaccinating chickens against Campylobacter could cut food poisoning in humans. Item

> GenVec has received a grant of around $600,000 over two years from NIAID to its malaria vaccine program. GenVec release

> Bavarian Nordic may seek government funding to support the development of its anthrax vaccine if its preclinical results are positive. Article

And Finally… Dr. Adel A.F. Mahmoud, previously president of Merck Vaccines and Merck's chief medical adviser for vaccines and infectious diseases, has joined the board of vaccine developer Inovio. Article
 

Suggested Articles

Daiichi Sankyo says it still unable to fulfill a government mandate to be able to produce enough H5N1 flu vaccine to fight an epidemic in Japan.

GSK’s Shingrix has continuously impressed industry watchers with its growth, and the company just added another large market to its list: China.

WuXi Biologics says it will build a dedicated facility to manufacture a commercial vaccine product for a client in a $3 billion contract.